Jung-Hyun Rho1,2, Jon J Ladd1,2, Christopher I Li1, John D Potter1,3,4, Yuzheng Zhang1, David Shelley1,2, David Shibata5, Domenico Coppola6, Hiroyuki Yamada7, Hidenori Toyoda8, Toshifumi Tada8, Takashi Kumada8, Dean E Brenner9,10, Samir M Hanash11, Paul D Lampe1,2. 1. Translational Research Program, Public Health Sciences Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 2. Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 3. School of Public Health, University of Washington, Seattle, Washington, USA17. 4. Centre for Public Health Research, Massey University, Wellington, New Zealand. 5. University of Tennessee Health Science Center, Memphis, Tennessee, USA. 6. Moffitt Cancer Center, Tampa, Florida, USA. 7. Wako Life Sciences, Inc., Mountain View, California, USA. 8. Department of Gastroenterology, Ogaki Municipal Hospital, Gifu, Japan. 9. Great Lakes New England (GLNE) Clinical Validation Center of EDRN, University of Michigan Medical Center, Ann Arbor, Michigan, USA. 10. VA Medical Center, Ann Arbor, Michigan, USA. 11. Department of Clinical Cancer Prevention, Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
OBJECTIVE: To discover and confirm blood-based colon cancer early-detection markers. DESIGN: We created a high-density antibody microarray to detect differences in protein levels in plasma from individuals diagnosed with colon cancer <3 years after blood was drawn (ie, prediagnostic) and cancer-free, matched controls. Potential markers were tested on plasma samples from people diagnosed with adenoma or cancer, compared with controls. Components of an optimal 5-marker panel were tested via immunoblotting using a third sample set, Luminex assay in a large fourth sample set and immunohistochemistry (IHC) on tissue microarrays. RESULTS: In the prediagnostic samples, we found 78 significantly (t-test) increased proteins, 32 of which were confirmed in the diagnostic samples. From these 32, optimal 4-marker panels of BAG family molecular chaperone regulator 4 (BAG4), interleukin-6 receptor subunit beta (IL6ST), von Willebrand factor (VWF) and CD44 or epidermal growth factor receptor (EGFR) were established. Each panel member and the panels also showed increases in the diagnostic adenoma and cancer samples in independent third and fourth sample sets via immunoblot and Luminex, respectively. IHC results showed increased levels of BAG4, IL6ST and CD44 in adenoma and cancer tissues. Inclusion of EGFR and CD44 sialyl Lewis-A and Lewis-X content increased the panel performance. The protein/glycoprotein panel was statistically significantly higher in colon cancer samples, characterised by a range of area under the curves from 0.90 (95% CI 0.82 to 0.98) to 0.86 (95% CI 0.83 to 0.88), for the larger second and fourth sets, respectively. CONCLUSIONS: A panel including BAG4, IL6ST, VWF, EGFR and CD44 protein/glycomics performed well for detection of early stages of colon cancer and should be further examined in larger studies. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: To discover and confirm blood-based colon cancer early-detection markers. DESIGN: We created a high-density antibody microarray to detect differences in protein levels in plasma from individuals diagnosed with colon cancer <3 years after blood was drawn (ie, prediagnostic) and cancer-free, matched controls. Potential markers were tested on plasma samples from people diagnosed with adenoma or cancer, compared with controls. Components of an optimal 5-marker panel were tested via immunoblotting using a third sample set, Luminex assay in a large fourth sample set and immunohistochemistry (IHC) on tissue microarrays. RESULTS: In the prediagnostic samples, we found 78 significantly (t-test) increased proteins, 32 of which were confirmed in the diagnostic samples. From these 32, optimal 4-marker panels of BAG family molecular chaperone regulator 4 (BAG4), interleukin-6 receptor subunit beta (IL6ST), von Willebrand factor (VWF) and CD44 or epidermal growth factor receptor (EGFR) were established. Each panel member and the panels also showed increases in the diagnostic adenoma and cancer samples in independent third and fourth sample sets via immunoblot and Luminex, respectively. IHC results showed increased levels of BAG4, IL6ST and CD44 in adenoma and cancer tissues. Inclusion of EGFR and CD44 sialyl Lewis-A and Lewis-X content increased the panel performance. The protein/glycoprotein panel was statistically significantly higher in colon cancer samples, characterised by a range of area under the curves from 0.90 (95% CI 0.82 to 0.98) to 0.86 (95% CI 0.83 to 0.88), for the larger second and fourth sets, respectively. CONCLUSIONS: A panel including BAG4, IL6ST, VWF, EGFR and CD44 protein/glycomics performed well for detection of early stages of colon cancer and should be further examined in larger studies. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
COLORECTAL ADENOMAS; COLORECTAL CANCER; COLORECTAL CANCER SCREENING; TUMOUR MARKERS
Authors: M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui Journal: J Natl Cancer Inst Date: 2001-07-18 Impact factor: 13.506
Authors: Polly A Newcomb; Barry E Storer; Libby M Morimoto; Allyson Templeton; John D Potter Journal: J Natl Cancer Inst Date: 2003-04-16 Impact factor: 13.506
Authors: Jon J Ladd; Tina Busald; Melissa M Johnson; Qing Zhang; Sharon J Pitteri; Hong Wang; Dean E Brenner; Paul D Lampe; Raju Kucherlapati; Ziding Feng; Ross L Prentice; Samir M Hanash Journal: Cancer Prev Res (Phila) Date: 2012-01-25
Authors: Christopher I Li; Justin E Mirus; Yuzheng Zhang; Arturo B Ramirez; Jon J Ladd; Ross L Prentice; Martin W McIntosh; Samir M Hanash; Paul D Lampe Journal: Breast Cancer Res Treat Date: 2012-08-19 Impact factor: 4.872
Authors: Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Theodore R Levin; Philip Lavin; Graham P Lidgard; David A Ahlquist; Barry M Berger Journal: N Engl J Med Date: 2014-03-19 Impact factor: 91.245
Authors: Joell L Solan; Lucrecia Marquez-Rosado; Paul L Sorgen; Perry J Thornton; Philip R Gafken; Paul D Lampe Journal: J Cell Biol Date: 2007-12-17 Impact factor: 10.539
Authors: Niels Lech Pedersen; Mathias Mertz Petersen; Jon J Ladd; Paul D Lampe; Robert S Bresalier; Gerard J Davis; Christina Demuth; Sarah Ø Jensen; Claus L Andersen; Linnea Ferm; Ib J Christensen; Hans J Nielsen Journal: Clin Chim Acta Date: 2020-04-06 Impact factor: 3.786
Authors: Kristin J Lastwika; Julia Kargl; Yuzheng Zhang; Xiaodong Zhu; Edward Lo; David Shelley; Jon J Ladd; Wei Wu; Paul Kinahan; Sudhakar N J Pipavath; Timothy W Randolph; Melissa Shipley; Paul D Lampe; A McGarry Houghton Journal: Am J Respir Crit Care Med Date: 2019-05-15 Impact factor: 21.405
Authors: Hafeez Afolabi; Salzihan Md Salleh; Zaidi Zakaria; Ch'ng Ewe Seng; Siti Norasikin Binti Mohd Nafil; Ahmad Aizat Bin Abdul Aziz; Yusuf Wada; Ahmad Irekeola Journal: Biomed Res Int Date: 2022-06-23 Impact factor: 3.246
Authors: Xiaoliang Wang; Ali Shojaie; Yuzheng Zhang; David Shelley; Paul D Lampe; Lisa Levy; Ulrike Peters; John D Potter; Emily White; Johanna W Lampe Journal: PLoS One Date: 2017-05-25 Impact factor: 3.240
Authors: Joëlle S Nader; Jérôme Abadie; Sophie Deshayes; Alice Boissard; Stéphanie Blandin; Christophe Blanquart; Nicolas Boisgerault; Olivier Coqueret; Catherine Guette; Marc Grégoire; Daniel L Pouliquen Journal: Oncotarget Date: 2018-03-27
Authors: Maria L Wikberg; Robin Myte; Richard Palmqvist; Bethany van Guelpen; Ingrid Ljuslinder Journal: Cancer Med Date: 2018-03-23 Impact factor: 4.452
Authors: Robert S Bresalier; William M Grady; Sanford D Markowitz; Hans Jørgen Nielsen; Surinder K Batra; Paul D Lampe Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-04-16 Impact factor: 4.254